
Eczema and eczematous reactions induced by interleukin (IL)‐17 inhibitors in patients with psoriasis are established adverse events (1), which may be reported as adverse events (AEs) in up to 12.1% patients on anti‐IL‐17 treatment in controlled clinical trials (2‐5). We performed an integrated safety analysis of 13 clinical studies to evaluate the frequency and management of the treatment‐emergent adverse events (TE‐AEs) of eczema and clinical variants in patients with moderate‐to‐severe psoriasis treated with ixekizumab (IXE),..
Like
Save
Share